# US 2023/0067484 A1 · Methods and compositions for genomic integration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0067484 A1
- Document ID: US20230067484A1
- Status: Published application
- Kind: A1
- Application number: 17/499,232
- Filed: 2021-10-12
- Published: 2023-03-02
- Earliest claimed: 2019-09-03
- Assignees: Myeloid Therapeutics, Inc.
- Applicants: Myeloid Therapeutics, Inc.
- Inventors: Daniel GETTS; Yuxiao Wang; Namita Bisaria; Inna Shcherbakova; Socheata Ly
- Web page: https://patentgrep.com/patent/US20230067484A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/45: Transferases (2)
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/32: against translation products of oncogenes
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/85: for animal cells
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C12N 15/907: {in mammalian cells}
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/09: containing a nuclear localisation signal
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/31: Combination therapy
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N 2800/90: Vectors containing a transposable element
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N 2840/203: having an IRES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.

## Claims

### Claim at position 1

-30. (canceled)

### Claim 31

A method of stably integrating a human insert sequence into genomic DNA of a target human cell, the method comprising:
(a) contacting a composition to the target cell, the composition comprising an RNA molecule, wherein the RNA molecule comprises:
(i) a human insert sequence, wherein the human insert sequence comprises a sequence that is a reverse complement of a sequence encoding an exogenous human therapeutic polypeptide, and
(ii) a human mobile genetic element comprising a sequence encoding a polypeptide, wherein the polypeptide encoded by the sequence of the human mobile genetic element promotes integration of the human insert sequence into genomic DNA via target-primed reverse transcription (TPRT); and
(b) stably integrating the human insert sequence into the genomic DNA of the target human cell; and
(c) expressing the exogenous human therapeutic polypeptide in the target human cell.

### Claim 32 (depends on 31)

The method of claim 31, wherein the polypeptide encoded by the sequence of the human mobile genetic element comprises a human ORF2p or a functional fragment thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein the RNA molecule is an mRNA molecule comprising the human insert sequence and the human mobile genetic element.

### Claim 34 (depends on 31)

The method of claim 31, wherein the target human cell is an immune cell selected from the group consisting of a T cell, a B cell, a myeloid cell, a monocyte, a macrophage and a dendritic cell.

### Claim 35 (depends on 32)

The method of claim 32, wherein the composition further comprises a sequence encoding a human ORF1p or a functional fragment thereof to the target cell.

### Claim 36 (depends on 35)

The method of claim 35, wherein the human ORF1p or functional fragment thereof and the human ORF2p or functional fragment thereof are translated from different open reading frames (ORFs) of the same RNA molecule.

### Claim 37 (depends on 35)

The method of claim 35, wherein different RNA molecules encode the human ORF1p or functional fragment thereof and the human ORF2p or functional fragment.

### Claim 38 (depends on 32)

The method of claim 32, wherein stably integrating comprises stably integrating the human insert sequence into the genomic DNA at a poly T site by endonuclease activity of an endonuclease domain of the human ORF2p.

### Claim 39 (depends on 38)

The method of claim 38, wherein the poly T site comprises the sequence TTTTTA.

### Claim 40 (depends on 32)

The method of claim 32, wherein the RNA molecule comprises homology arms complementary to a target site in the genomic DNA.

### Claim 41 (depends on 31)

The method of claim 31, wherein stably integrating comprises stably integrating the human insert sequence into non-ribosomal genomic DNA of the target human cell or stably integrating the human insert sequence into the genomic DNA at a locus that is not an rDNA locus.

### Claim 42 (depends on 31)

The method of claim 31, wherein the composition further comprises (i) one or more siRNAs and/or (ii) an RNA guide sequence or a polynucleic acid encoding the RNA guide sequence, and wherein the RNA guide sequence targets a DNA target site of the genomic DNA and the human insert sequence is integrated into the genomic DNA at the DNA target site of the genomic DNA.

### Claim 43 (depends on 31)

The method of claim 31, wherein the RNA molecule has a total length of from 3 kb to 20 kb.

### Claim 44 (depends on 31)

The method of claim 31, wherein contacting comprises administering the composition to a human subject.

### Claim 45 (depends on 31)

The method of claim 31, wherein the exogenous human therapeutic polypeptide is selected from the group consisting of a ligand, an antibody, a receptor, an enzyme, a transport protein, a structural protein, a hormone, a contractile protein, a storage protein and a transcription factor.

### Claim 46 (depends on 45)

The method of claim 45, wherein the exogenous human therapeutic polypeptide is a receptor selected from the group consisting of a chimeric antigen receptor (CAR) and a T cell receptor (TCR).

### Claim 47 (depends on 31)

The method of claim 31, wherein the exogenous human therapeutic polypeptide is a receptor selected from the group consisting of a chimeric antigen receptor (CAR) and a T cell receptor (TCR), and wherein the composition is a pharmaceutical composition formulated for systemic administration to a human subject.

### Claim 48 (depends on 32)

The method of claim 32, wherein the RNA molecule comprises a first expression cassette comprising a promoter sequence, a 5′ UTR sequence, a 3′ UTR sequence and a poly A sequence; wherein:
(i) the promoter sequence is upstream of the 5′ UTR sequence,
(ii) the 5′ UTR sequence is upstream of the sequence of the human mobile genetic element encoding a polypeptide,
(iii) the 3′ UTR sequence is downstream of the human insert sequence; and
(iv) the 3′ UTR is upstream of the poly A sequence; and
wherein the 5′ UTR sequence, the 3′ UTR sequence or the poly A sequence comprises a binding site for the human ORF2p or a functional fragment thereof.

### Claim 49 (depends on 48)

The method of claim 48, wherein the human insert sequence comprises a second expression cassette comprising a sequence that is a reverse complement of a promoter sequence, a sequence that is a reverse complement of a 5′ UTR sequence, a sequence that is a reverse complement of a 3′ UTR sequence and a sequence that is a reverse complement of a poly A sequence; wherein:
(i) the sequence that is a reverse complement of a promoter sequence is downstream of the sequence that is a reverse complement of a 5′ UTR sequence,
(ii) the sequence that is a reverse complement of a 5′ UTR sequence is downstream of the sequence that is a reverse complement of the sequence encoding an exogenous human therapeutic polypeptide,
(iii) the sequence that is a reverse complement of a 3′ UTR sequence is upstream of the sequence that is a reverse complement of the sequence encoding an exogenous human therapeutic polypeptide, and
(iv) the sequence that is a reverse complement of a poly A sequence is upstream of the sequence that is a reverse complement of a 3′ UTR sequence and downstream of the sequence of the human mobile genetic encoding a polypeptide.

### Claim 50 (depends on 49)

The method of claim 49, wherein the promoter sequence of the first expression cassette is different from the promoter sequence of the second expression cassette.

### Claim 51 (depends on 32)

The method of claim 32, wherein the RNA molecule comprises a 5′ UTR sequence and a 3′ UTR sequence, wherein
(a) the 5′ UTR comprises a 5′ UTR from LINE-1; and/or
(b) the 3′ UTR comprises a 3′ UTR from LINE-1.

### Claim 52 (depends on 31)

The method of claim 31, wherein the sequence encoding the exogenous human therapeutic polypeptide does not comprise introns.

### Claim 53 (depends on 31)

The method of claim 31, wherein the polypeptide encoded by the sequence of the human mobile genetic element comprises a C-terminal nuclear localization signal (NLS), an N-terminal NLS, or both.

### Claim 54 (depends on 31)

The method of claim 31, wherein the RNA molecule comprises a sequence encoding a nuclease domain, wherein the nuclease domain is a nuclease domain from megaTAL, TALEN, Cas9, Cash, Cas7, or Cas8; wherein the nuclease domain is not from ORF2p.

### Claim 55 (depends on 54)

The method of claim 54, wherein the RNA molecule comprises a sequence encoding the nuclease domain, wherein the nuclease domain does not have nuclease activity or comprises a mutation that reduces activity of the nuclease domain compared to the nuclease domain without the mutation.

### Claim 56 (depends on 32)

The method of claim 32, wherein the sequence encoding the exogenous human therapeutic polypeptide is not in frame with a sequence encoding the human ORF2p or functional fragment thereof.

### Claim 57 (depends on 32)

The method of claim 32, wherein the human ORF2p or functional fragment thereof is a modified human ORF2p that lacks endonuclease activity or has reduced endonuclease activity compared to wild type human ORF2p.

### Claim 58 (depends on 57)

The method of claim 57, wherein the modified human ORF2p comprises a mutation selected from the group consisting of S228P and Y1180A as compared to SEQ ID NO: 55.

### Claim 59 (depends on 31)

The method of claim 31, wherein the RNA molecule
(i) is formulated in a nanoparticle selected from the group consisting of a lipid nanoparticle and a polymeric nanoparticle; and/or
(ii) comprises a glycosylated RNA molecule, a circular RNA molecule or a self-replicating RNA molecule.

### Claim 60 (depends on 32)

The method of claim 32, wherein the polypeptide encoded by the sequence of the human mobile genetic element comprises a sequence with at least 90% sequence identity to SEQ ID NO: 55.
